



# Biotech Daily

Monday March 15, 2021

*Daily news on ASX-listed biotechnology companies*

## Actinogen Appoints Dr Steven Gourlay CEO On \$400k

### [ACTINOGEN MEDICAL](#)

Actinogen says it has appointed Dr Steven Gourlay as its chief executive officer, effective from today and starting on a base salary of \$400,000 a year.

Actinogen said the Sydney-based Dr Gourlay had more than 30 years' experience in novel therapeutics development, was previously the founding chief medical officer of US-based Principia Biopharma and a partner at Melbourne's GBS Venture Partners co-founded by Actinogen chair Dr Geoff Brooke.

The company said that Dr Gourlay would be paid a base salary of \$400,000 a year including superannuation and leave entitlements, a short-term incentive bonus up-to 35 percent of the annual salary, or more for "exceptional performance", along with interest-free loan shares as a long-term incentive, including 24,181,150 shares at 3.5 cents a share, and 24,181,150 shares at 4.5 cents a share.

Actinogen said Dr Gourlay held a Bachelor of Medicine, Bachelor of Surgery from the University of Melbourne, a Doctor of Medicine from Melbourne's Monash University and a Master of Business Administration from Sydney's Macquarie University.

Actinogen was up 0.2 cents or eight percent to 2.7 cents with 39.4 million shares traded.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053  
email: [editor@biotechdaily.com.au](mailto:editor@biotechdaily.com.au); [www.biotechdaily.com.au](http://www.biotechdaily.com.au); twitter: @biotech\_daily